H. Mishima

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

Shigeyoshi Iwamoto, Tsuyoshi Takahashi, Hiroshi Tamagawa et al. · Annals of Oncology · 2015 · 66 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms

Yusuke Okuyama, Shoichi Hazama, Hiroshi Nozawa et al. · Japanese Journal of Clinical Oncology · 2011 · 54 citations · Full text

Medicine, Genetics, Oncology +16

The Importance of Evaluation of DNA Amplificability in KRAS Mutation Testing with Dideoxy Sequencing using Formalin-fixed and Paraffin-embedded Colorectal Cancer Tissues

Naoko Okayama, M. Nishioka, Shoichi Hazama et al. · Japanese Journal of Clinical Oncology · 2010 · 23 citations · Full text

Medicine, Genetics, Oncology +17

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

Yoshinori Munemoto, Masato Nakamura, Masazumi Takahashi et al. · European Journal of Cancer · 2019 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16

Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study

Tadafumi Kato, Kei Muro, Kensei Yamaguchi et al. · Annals of Oncology · 2011 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +12